Ifscheiber wrote: "why not leave out the comments on titration, then they can go to market without violating the patent, ... ahh wait, then FDA would not allow their product to be sold"
That is the quick reason why Corcept has said all along that they are confident that they will prevail. Teva's bet was to invalidate the patent via the IPR and then via appealing the IPR decision. They lost that so there will be no at-risk launch. The rest of the process at district court has been legal maneuvering and the back and forth in hopes that somehow, they can salvage something.
Corcept has been unwilling to settle so the process (to just makes things go away) will go on and on until the beyond Rela readout. If that is positive (shows that it is as good on efficacy as Mife) the game over.